FDA reviewing CSL's CSL830 for HAE prophylaxis

FDA accepted for review a BLA from CSL Ltd. (ASX:CSL) for CSL830 ( subcutaneous C1-INH) to prevent hereditary angioedema (HAE) attacks. The therapy is a low-volume, subcutaneous complement 1 (C1) este...